Alveo Technologies is partnering with the University of Texas Medical Branch to develop a molecular point-of-care diagnostic test for #Lassa fever, a hemorrhagic illness endemic in parts of West Africa for which access to laboratory testing is limited. www.ghtcoalition.org/blog/researc...

Research Roundup: Ebola vaccine candidate, Lassa virus test, Gonorrhea antibiotic approval

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

Science alone won't stop an outbreak. Join Elizabeth Talbot and Elizabeth Wrobel for a discussion on the 2026 Bundibugyo Ebola outbreak and how conflict, trust, & access are shaping the response alongside advances in vaccines and diagnostics. 🔗 asm.social/32b

We are so excited to welcome our newest member Maisha Meds! Maisha builds user-driven software that helps private pharmacies and clinics deliver quality, affordable care while growing stronger businesses. www.ghtcoalition.org/our-members/...

Last week, the Merck-Wellcome joint venture Hilleman Laboratories announced that it will manufacture doses of a promising vaccine candidate for the #Bundibugyo strain of Ebola, which is behind the worrying outbreak in DRC. www.ghtcoalition.org/blog/researc...

The cost of responding to antimalarial drug resistance in Africa will only grow as resistance spreads. Beyond new #malaria medicines, investment must also target surveillance, health systems and local manufacturing. More: bit.ly/4pP8Ilm

When Will Malaria Meds Stop Working In Africa?

“The continent should take the matter of resistance very, very seriously...Resistance should be seen as an emergency situation.”

bit.ly

CARB-X Executive Director Kevin Outterson will testify today as a witness at a Senate Finance Committee Subcommittee on Health Care Hearing. Antibiotics are essential healthcare infrastructure, yet they remain undervalued and underinvested in. #PoliSky 🎥 bit.ly/45D0AuM

What's new in #GlobalHealth R&D? 💉#Ebola vaccine candidate production 🧪#Lassa virus test ✅#Gonorrhea antibiotic approval www.ghtcoalition.org/blog/researc...

The success of breakthrough #HIV prevention drug #lenacapavir shows how sustained investment and collaboration from early research to global scale-up can help ensure breakthrough tools rapidly and inclusively move from lab to community. #GlobalHealth www.ghtcoalition.org/blog/lenacap...

Lenacapavir: A blueprint for innovation, regulation, and access

At a pivotal moment for HIV innovation, the historic journey of the HIV prevention drug lenacapavir from the lab to the clinic offers an important blueprint for how sustained investment in and coordin...

ghtcoalition.org

As leaders gather at #AIDS2026, lenacapavir offers important lessons for the future of #HIV and #globalhealth innovation. Scientific breakthroughs achieve their full potential when innovation, regulation, financing, and access efforts advance together. www.ghtcoalition.org/blog/lenacap...

Lenacapavir: A blueprint for innovation, regulation, and access

At a pivotal moment for HIV innovation, the historic journey of the HIV prevention drug lenacapavir from the lab to the clinic offers an important blueprint for how sustained investment in and coordin...

ghtcoalition.org

Breakthroughs reach their full potential only when people can access them. The path of #HIV drug #lenacapavir from trials to approval to rollout highlights the importance of collaboration between researchers, regulators, funders, and communities. www.ghtcoalition.org/blog/lenacap...

Lenacapavir: A blueprint for innovation, regulation, and access

At a pivotal moment for HIV innovation, the historic journey of the HIV prevention drug lenacapavir from the lab to the clinic offers an important blueprint for how sustained investment in and coordin...

ghtcoalition.org

#Lenacapavir shows what’s possible when the R&D system works together. Early research to historic clinical trials to international regulatory collaborations have helped move this game-changing #HIV prevention drug from lab to impact at unprecedented speed.

Lenacapavir: A blueprint for innovation, regulation, and access

At a pivotal moment for HIV innovation, the historic journey of the HIV prevention drug lenacapavir from the lab to the clinic offers an important blueprint for how sustained investment in and coordin...

ghtcoalition.org

#GlobalHealth innovation requires more than scientific ingenuity—it requires sustained investment. This story highlights how USAID funding terminations threatened a promising African-led HIV vaccine effort, putting hard-won research progress at risk. www.vox.com/future-perfe...

An HIV vaccine is within reach

But politics could derail the one thing to unlock it.

vox.com

What's new in #GlobalHealth R&D? 💊#HIV treatment interim findings 🥼#Ebola vaccine study 💉#TB vaccine trial www.ghtcoalition.org/blog/researc...

Research Roundup: HIV treatment interim findings, Ebola vaccine study, TB vaccine trial

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

@medicinespatentpool.org and @pentafoundation.bsky.social are pleased to announce the signing of a MoU to strengthen collaboration in support of equitable #access to priority health technologies for #children in LMICs. 👉 medicinespatentpool.org/partners/who... #AIDS2026

A Phase 1 trial of a @cepi.net -backed #Bundibugyo ebolavirus vaccine candidate launched last week, making it the first vaccine candidate to enter clinical testing in the response to the ongoing outbreak in the Democratic Republic of Congo. www.ghtcoalition.org/blog/researc...

Research Roundup: TB vaccine candidate manufacturing deal, Promising malaria drug candidate results, Bundibugyo vaccine trial launch

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

Last week, experts came together in a webinar to reflect on the last 10 years of #mycetoma progress and look at future priorities to tackle this devastating disease. If you missed it, listen to the audio recording here: www.youtube.com/watch?v=scke...

A decade of mycetoma advocacy and research (webinar audio recording)

YouTube video by Drugs for Neglected Diseases initiative (DNDi)

youtube.com

Biological threats are rising, and preparedness is not keeping pace. The new 2026 Africa Health Security Index shows where countries have strengthened capacities and where the gaps remain. Learn more: AHSIndex.org

The Africa Health Security Index

An independent assessment of epidemic and pandemic preparedness across Africa.

ahsindex.org

A Phase 1 trial cosponsored by @mmv.org evaluating a potential #malaria treatment found promising results, as the growing threat of resistance of the malaria parasite to first-line therapies has underscored the urgent need for new antimalarials. www.ghtcoalition.org/blog/researc...

Research Roundup: TB vaccine candidate manufacturing deal, Promising malaria drug candidate results, Bundibugyo vaccine trial launch

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

Last week, @seruminstindia.bsky.social announced that it will manufacture a promising #tuberculosis vaccine candidate in late-stage development under an agreement with Gates MRI. www.ghtcoalition.org/blog/researc...

Research Roundup: TB vaccine candidate manufacturing deal, Promising malaria drug candidate results, Bundibugyo vaccine trial launch

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

A major milestone for GARDP's #NeoSep1 trial 🎉 The first baby has now been enrolled in Vietnam, continuing the expansion of this landmark neonatal sepsis trial from Africa into Asia.

CARB-X is proud to be the push incentive partner for NeoTest, a new @cgdev.org initiative that aims to accelerate the development, commercialization, and adoption of rapid diagnostics for neonatal sepsis in LMICs. #IDSky 🧪 🔗

What's new in #GlobalHealth R&D? 💉 #TB vaccine candidate manufacturing deal 💊Promising #malaria drug candidate results 🥼 #Bundibugyo vaccine trial launch www.ghtcoalition.org/blog/researc...

Research Roundup: TB vaccine candidate manufacturing deal, Promising malaria drug candidate results, Bundibugyo vaccine trial launch

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

There are 5 million deaths associated with #AMR yearly & AMR-related deaths are projected to rise at unprecedented rates, yet the current pipeline is insufficient. Learn more about research successes, missing tools, & innovations in development. ➡️bit.ly/AMR-FS

🌍 The #NeoSep1 clinical trial, an international effort to improve treatment options for newborns with #sepsis, has expanded to Asia. In Africa, the trial is embedded within the SNIP-AFRICA project, funded by Global Health EDCTP3. 🔗 Read more: penta-id.org/news/neosep1...

🎉 Our annual report is out! In 2025, we advanced work on 📋 33 projects, including 🔬 13 clinical trials in 6 disease areas, conducted across 📍 41 sites in 🌍 16 countries. To every partner and supporter standing with us: thank you 🙏 🔗 dndi.org/about/annual...

🌍Africa bears a high burden of infectious diseases, but funding for priority #diagnostics continues to decline. Impact Global Health and PATH’s new Diagnostics Deficit report explores what’s needed to close the gap. 🔗Learn more: https://bit.ly/4w8WV3E

Last week, global partners initiated a Phase 1 clinical trial to assess the safety and pharmacokinetic profile of a promising broadly neutralizing antibody developed by IAVI for eventual use to prevent #HIV acquisition by infants and young children. www.ghtcoalition.org/blog/researc...

Research Roundup: New dengue treatment trial, Shigella vaccine trial results, HIV bnAb trial launch

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

ghtcoalition.org

🌍 🔎 Today, Impact Global Health and @path.org publish The Diagnostics Deficit, the second in our Blindspots series. We ask whether Africa's diagnostics landscape is keeping pace with the continent's disease burden. Answer: not yet, but the gap is closeable. Read the snapshot here: shorturl.at/3qTx2

The diagnostics deficit: Funding, access, and preparedness gaps in African health systems

The second publication in the R&D Blindspots Policy Series turns to a critical question for the continent: does Africa have the diagnostics needed to detect, respond to, and stay ahead of its epidemic...

shorturl.at

#PressRelease A potential new antimalarial has shown promising results in its first study in humans. The investigational non-artemisinin medicine rapidly killed #malaria parasites and was generally well tolerated in infected volunteers. Read more: bit.ly/3T5KJ4Y

New malaria drug candidate shows early promise in human study | Medicines for Malaria Venture

bit.ly

A new study published in The Lancet Infectious Diseases demonstrated promising results for an investigational vaccine candidate for Shigella sonnei, an important step toward developing a vaccine for the disease-causing bacteria. www.ghtcoalition.org/blog/researc...